Olimab 60mg injection

Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately.

Some common side effects of Olimab 60mg Injection include:

• Rash
  
• Musculoskeletal (bone, muscle or joint) pain
  
• Eczema
  
• Upper respiratory tract infection
  
• Sciatica
  
• Pain in extremities
  
• Back pain
  
• Joint pain
  
• Urinary tract infection
  
• Constipation
  
• Abdominal discomfort
  
• Hair loss
  
• Hypercholesterolemia (high cholesterol)
  
• Cystitis
  
• Nerve pain
  
• Headache
  
  

Olimab 60mg Injection is a powerful monoclonal antibody. that can only be given by a doctor or nurse under strict medical supervision.

It is not self-administerable. Dosage and duration of the treatment are determined by the doctor as per the patient's health condition and type of the disease.

Olimab 60mg Injection contains Denosumab as an active ingredient that is a monoclonal antibody. It makes the bones strong as well as reduces the risk of fractures. It works by binding to a protein that causes bone loss, thereby strengthening the bone and minimizing the risk of fractures.

• Burkiewicz, J. S., Scarpace, S. L., & Bruce, S. P. (2009). Denosumab in osteoporosis and oncology. Annals of Pharmacotherapy, 43(9), 1445-1455.
  
• Miyazaki, T., Tokimura, F., & Tanaka, S. (2014). A review of denosumab for the treatment of osteoporosis. Patient preference and adherence, 463-471.
  
• Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., ... & Christiansen, C. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361(8), 756-765.
  
• Deeks, E. D. (2018). Denosumab: a review in postmenopausal osteoporosis. Drugs & aging, 35(2), 163-173.
  
• Kendler, D. L., Cosman, F., Stad, R. K., & Ferrari, S. (2022). Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Advances in therapy, 39(1), 58-74.
  
• Zaheer, S., LeBoff, M., & Lewiecki, E. M. (2015). Denosumab for the treatment of osteoporosis. Expert opinion on drug metabolism & toxicology, 11(3), 461-470.​